Current and future treatment options in non-alcoholic steatohepatitis (NASH)

Effects of dark chocolate on NOX-2-generated oxidative stress in patients with non-alcoholic steatohepatitis

(2016) L. Loffredo et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design

(2016) Scott Friedman et al.   Contemporary Clinical Trials

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

(2016) Vlad Ratziu et al.   GASTROENTEROLOGY

Regulatory Science and Drug Approval for Alcoholic and Nonalcoholic Steatohepatitis

(2016) Arun J. Sanyal et al.   GASTROENTEROLOGY

Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease

(2016) Yaron Rotman et al.   GUT

Late-breaking abstracts

(2016)   HEPATOLOGY

Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES

(2016) Tracey G. Simon et al.   HEPATOLOGY

Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir)

(2016) Nathalie Ganne-Carrié et al.   HEPATOLOGY

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

(2016)   JOURNAL OF HEPATOLOGY

Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial

(2016) Jeffrey Cui et al.   JOURNAL OF HEPATOLOGY

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

(2016) Matthew James Armstrong et al.   LANCET

The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)

(2016) Elena Buzzetti et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies

(2016) Giovanni Musso et al.   NATURE REVIEWS DRUG DISCOVERY

Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice

(2016) Takaya Yamamoto   WORLD JOURNAL OF GASTROENTEROLOGY

Fibroblast growth factor 19-targeted therapies for the treatment of metabolic disease

(2015) Jacek Rysz et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis

(2015) Eduardo Vilar-Gomez et al.   GASTROENTEROLOGY

Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients

(2015) Guillaume Lassailly et al.   GASTROENTEROLOGY

Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study

(2015) Edith M. Koehler et al.   HEPATOLOGY

Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)

(2015) Rohit Loomba et al.   HEPATOLOGY

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

(2015) Mattias Ekstedt et al.   HEPATOLOGY

Physical activity and liver diseases

(2015) Annalisa Berzigotti et al.   HEPATOLOGY

Double-blind Randomized Placebo-controlled Clinical Trial of Omega 3 Fatty Acids for the Treatment of Diabetic Patients With Nonalcoholic Steatohepatitis

(2015) Srinivasan Dasarathy et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Oral Administration of OKT3 MAb to Patients with NASH, Promotes Regulatory T-cell Induction, and Alleviates Insulin Resistance: Results of a Phase IIa Blinded Placebo-Controlled Trial

(2015) Gadi Lalazar et al.   JOURNAL OF CLINICAL IMMUNOLOGY

LP37 : A placebo-controlled, multicenter, double-blind, randomised trial of emricasan in subjects with non-alcoholic fatty liver disease (NAFLD) and raised transaminases

(2015) M. Shiffman et al.   JOURNAL OF HEPATOLOGY

PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis

(2015) Sven Francque et al.   JOURNAL OF HEPATOLOGY

Effect of aerobic exercise training dose on liver fat and visceral adiposity

(2015) Shelley E. Keating et al.   JOURNAL OF HEPATOLOGY

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Polyphenols and non-alcoholic fatty liver disease: impact and mechanisms

(2015) I. Rodriguez-Ramiro et al.   PROCEEDINGS OF THE NUTRITION SOCIETY

Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome

(2015) Konstantinos Kargiotis   WORLD JOURNAL OF GASTROENTEROLOGY

Lack of Efficacy of an Inhibitor of PDE4 in Phase 1 and 2 Trials of Patients With Nonalcoholic Steatohepatitis

(2014) Vlad Ratziu et al.   Clinical Gastroenterology and Hepatology

The Fatty Acid–Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease

(2014) Rifaat Safadi et al.   Clinical Gastroenterology and Hepatology

Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis

(2014) Yun-A. Jung et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Total Body Weight Loss of ≥10 % Is Associated with Improved Hepatic Fibrosis in Patients with Nonalcoholic Steatohepatitis

(2014) Lisa M. Glass et al.   DIGESTIVE DISEASES AND SCIENCES

No Significant Effects of Ethyl-Eicosapentanoic Acid on Histologic Features of Nonalcoholic Steatohepatitis in a Phase 2 Trial

(2014) Arun J. Sanyal et al.   GASTROENTEROLOGY

Bariatric Surgery Improves Histological Features of Nonalcoholic Fatty Liver Disease and Liver Fibrosis

(2014) Andrew A. Taitano et al.   JOURNAL OF GASTROINTESTINAL SURGERY

Collagen proportionate area is superior to other histological methods for sub-classifying cirrhosis and determining prognosis

(2014) Emmanuel Tsochatzis et al.   JOURNAL OF HEPATOLOGY

The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis

(2014) Fernando J. Barreyro et al.   LIVER INTERNATIONAL

Randomized, Vitamin E-Controlled Trial of Bicyclol Plus Metformin in Non-Alcoholic Fatty Liver Disease Patients with Impaired Fasting Glucose

(2013) Ying Han et al.   CLINICAL DRUG INVESTIGATION

Dual Peroxisome Proliferator-Activated Receptor  /  Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects

(2013) B. Cariou et al.   DIABETES CARE

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

(2013) Sunder Mudaliar et al.   GASTROENTEROLOGY

Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease: a meta-analysis of 43 175 individuals

(2013) Silvia Sookoian et al.   GUT

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

(2013) Bart Staels et al.   HEPATOLOGY

The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease

(2013) Marno C. Ryan et al.   JOURNAL OF HEPATOLOGY

The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology and the American Gastroenterological Association

(2012) Naga Chalasani et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Obesity and Severe Obesity Forecasts Through 2030

(2012) Eric A. Finkelstein et al.   AMERICAN JOURNAL OF PREVENTIVE MEDICINE

Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies

(2012) Hsiao-Ping Chen et al.   GUT

Liver collagen proportionate area predicts decompensation in patients with recurrent hepatitis C virus cirrhosis after liver transplantation

(2012) Vincenza Calvaruso et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Treatment of non-alcoholic steatohepatitis withPhyllanthus urinaria: A randomized trial

(2012) Vincent Wai-Sun Wong et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Exercise and non-alcoholic fatty liver disease: A systematic review and meta-analysis

(2012) Shelley E. Keating et al.   JOURNAL OF HEPATOLOGY

Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD)

(2012) Winston Dunn et al.   JOURNAL OF HEPATOLOGY

Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease

(2012) Matteo Nicola Dario Di Minno   WORLD JOURNAL OF GASTROENTEROLOGY

Effects of the New Dual PPAR /  Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism

(2011) B. Cariou et al.   DIABETES CARE

Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States

(2011) Michael R. Charlton et al.   GASTROENTEROLOGY

Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss

(2011) K. Hallsworth et al.   GUT

Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: A 12-month randomized, prospective, open- label trial

(2011) Dawn M. Torres et al.   HEPATOLOGY

Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects

(2011) Sven Haufe et al.   HEPATOLOGY

Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study

(2011) Hideyuki Hyogo et al.   HEPATOLOGY RESEARCH

Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents

(2011) Joel E. Lavine   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Vitamin E and the Risk of Prostate Cancer

(2011) Eric A. Klein et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

l-Carnitine Supplementation to Diet: A New Tool in Treatment of Nonalcoholic Steatohepatitis—A Randomized and Controlled Clinical Trial

(2010) Mariano Malaguarnera et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Pioglitazone: side effect and safety profile

(2010) Priya Shah et al.   Expert Opinion On Drug Safety

Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study

(2010) Christopher D. Williams et al.   GASTROENTEROLOGY

Smoking is associated with histological severity in nonalcoholic steatohepatitis

(2010) Emmanuel A. Tsochatzis et al.   HEPATOLOGY

Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease

(2010) Manal F. Abdelmalek et al.   HEPATOLOGY

High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial

(2010) Ulrich F. H. Leuschner et al.   HEPATOLOGY

Effects of Diet and Physical Activity Interventions on Weight Loss and Cardiometabolic Risk Factors in Severely Obese Adults

(2010) Bret H. Goodpaster et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease

(2010) Claudia O. Zein et al.   JOURNAL OF HEPATOLOGY

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

(2010) Vasilios G Athyros et al.   LANCET

Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C Virus 1 year after liver transplantation

(2010) Pinelopi Manousou et al.   LIVER TRANSPLANTATION

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

(2010) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease

(2009) E. VILAR GOMEZ et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Statins Are Associated With a Reduced Risk of Hepatocellular Carcinoma in a Large Cohort of Patients With Diabetes

(2009) Hashem B. El–Serag et al.   GASTROENTEROLOGY

Prospective Study of the Long-Term Effects of Bariatric Surgery on Liver Injury in Patients Without Advanced Disease

(2009) Philippe Mathurin et al.   GASTROENTEROLOGY

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

(2009) Kittichai Promrat et al.   HEPATOLOGY

Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial

(2009) Vlad Ratziu et al.   HEPATOLOGY

Decreased survival of subjects with elevated liver function tests during a 28-year follow-up

(2009) Cecilia Söderberg et al.   HEPATOLOGY

Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss

(2009) Nathan A. Johnson et al.   HEPATOLOGY

A Pilot Study Using Simvastatin in the Treatment of Nonalcoholic Steatohepatitis

(2009) Austin Nelson et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

(2009) Arne Astrup et al.   LANCET

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

(2009) Philip D Home et al.   LANCET

Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation

(2009) Philippe Lefebvre et al.   PHYSIOLOGICAL REVIEWS

The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial

(2009) William W. Shields et al.   Therapeutic Advances in Gastroenterology

Fatty liver, insulin resistance, and dyslipidemia

(2008) Martin Adiels et al.   Current Diabetes Reports

Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial

(2008) Vlad Ratziu et al.   GASTROENTEROLOGY

Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis

(2008) Guruprasad P. Aithal et al.   GASTROENTEROLOGY

High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease

(2008) K Kantartzis et al.   GUT

Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial

(2008) Stephen A. Harrison et al.   HEPATOLOGY